Exclusive Financial Advisor to Merit Medical Systems, Inc. on its Asset Purchase of EndoGastric Solutions, Inc.

Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit”), a global leader of healthcare technology announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for total cash consideration of approximately $105 million.

The product delivers a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD. By restoring the body’s reflux barrier, the acquired EsophyX Z+ device is designed to provide relief of GERD symptoms and reduce acid reflux that can cause long-term complications and risk. This is accomplished under endoscopic visualization during a minimally invasive procedure called Transoral Incisionless Fundoplication. The assets acquired from EndoGastric Solutions generated approximately $26 million of revenue over the twelve-month period ended December 31, 2023 and are expected to contribute $13 to $15 million for the six-months ending December 31, 2024.

Merit is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. As of July 1, 2024, Merit had a market capitalization of $5.0 billion and generated revenue of $1.3 billion over the twelve-month period ending March 31, 2024. Merit employs approximately 7,000 people worldwide and is headquartered in South Jordan, Utah.